Study on treatment with Risankizumab for psoriatic arthritis
Part of Bones, joints & muscles, Skin clinical trials.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have psoriatic arthritis that started at least 6 months ago
- You should have tried at least one standard arthritis medicine without enough improvement, or you cannot take those medicines
- You cannot have tried and failed 3 or more advanced biologic or targeted medicines
- Your doctor must confirm you have active psoriatic arthritis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study is for people with psoriatic arthritis who have already completed a year-long treatment with zasocitinib or a similar medicine in a previous study. It tests whether continuing to take zasocitinib remains safe and helpful over a longer time.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
This study looks at pregnancy outcomes in people who took risankizumab during pregnancy (or shortly before getting pregnant). It compares them with pregnancies exposed to similar biologic medicines, to better understand risks and what to expect.
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.